1.400044 重庆,重庆大学医学院
2.400014 重庆,重庆市急救医疗中心(重庆大学附属中心医院)心血管内科
3.400042 重庆,重庆医科大学附属第一医院心血管内科
Received:02 September 2024,
Revised:2024-11-07,
Published:30 December 2024
移动端阅览
Jialin ZHONG, Ruonan XIAO, Shuting XIANG, et al. Relationship between clonal hematopoiesis of indeterminate potential and severity of coronary stenosis in coronary heart disease patients with renal insufficiency[J]. Journal of Army Medical University, 2024, 46(24): 2765-2771.
Jialin ZHONG, Ruonan XIAO, Shuting XIANG, et al. Relationship between clonal hematopoiesis of indeterminate potential and severity of coronary stenosis in coronary heart disease patients with renal insufficiency[J]. Journal of Army Medical University, 2024, 46(24): 2765-2771. DOI: 10.16016/j.2097-0927.202409009.
目的
2
探讨潜能未定的克隆性造血(clonal hematopoiesis of indeterminate potential
CHIP)与肾功能不全的冠状动脉粥样硬化性心脏病(coronary heart disease
CHD)患者冠状动脉狭窄程度的关联。
方法
2
采用病例-对照研究设计方案
纳入2023年12月至2024年7月在重庆市急救医疗中心(重庆大学附属中心医院)和重庆医科大学附属第一医院心血管内科就诊的肾功能不全的CHD患者70例
根据Gensini评分中位数水平分为Gensini评分 < 44分组(34例)和Gensini评分≥44分组(36例)
根据是否携带CHIP突变分为CHIP组(23例)、非CHIP组(47例)
分别比较组间临床资料的差异。采用二元Logistic回归分析评估CHIP状态与冠脉病变程度的关系。
结果
2
与Gensini评分
<
44分组比较
Gensini评分≥44分组具有更高的CHIP携带率(17.6%
vs
47.2%
P
=0.008)以及NT-proBNP水平(767
vs
3 480 ng/L
P
=0.039)。二元Logistic回归分析显示
在校正NT-proBNP后
CHIP携带仍与较高的Gensini评分相关(
OR
=3.935
95%
CI
: 1.153~13.435
P
=0.029)。进一步按CHIP分组结果提示
与非CHIP组患者比较
CHIP组患者具有较高的Gensini评分(48
vs
38
P
=0.004)、更高的冠脉3支血管病变比例(52.2%
vs
25.5%
P
=0.040)和较低的左心室射血分数(55.0%
vs
58.0%
P
=0.042)。
结论
2
CHIP是肾功能不全CHD患者严重冠脉病变的独立危险因素。
Objective
2
To investigate the association between clonal hematopoiesis of indeterminate potential (CHIP) and the severity of coronary artery lesions in coronary heart disease (CHD) patients with renal insufficiency.
Methods
2
A case-control trial was conducted on 70 CHD patients with renal insufficiency admitted in Chongqing Emergency Medical Center (Affiliated Central Hospital of Chongqing University) and Department of Cardiovascular Diseases of the First Affiliated Hospital of Chongqing Medical University from December 2023 to July 2024.According to the median Gensini score
they were classified into the Gensini score
<
44 grou
p (
n
=34) and ≥44 group (
n
=36)
and based on carrying CHIP mutation or not
they were divided into CHIP group (
n
=23) and non-CHIP group (
n
=47).The differences in clinical data were compared between the above 2 pair groups respectively.Binary logistic regression analysis was used to assess the relationship between CHIP status and the severity of coronary artery lesions.
Results
2
Compared with the Gensini score
<
44 group
the Gensini score ≥44 group had a higher CHIP carriage rate (17.2%
vs
47.6%
P
=0.008) as well as NT-proBNP level (767
vs
3 480 ng/L
P
=0.039).Binary logistic regression analysis showed that CHIP status was still associated with higher Gensini scores after adjustment of NT-proBNP (
OR
=3.935
95%
CI
=1.153~13.435
P
=0.029).Further CHIP grouping results suggested that the patients in the CHIP group had higher Gensini score (48
vs
38
P
=0.004)
larger proportion of 3-vessle disease (52.2%
vs
25.5%
P
=0.040)
and lower left ventricular ejection fraction (55.0%
vs
58.0%
P
=0.042) than those in the non-CHIP group.
Conclusion
2
CHIP is an independent risk factor for severe coronary artery disease in CHD patients with renal insufficiency.
LIBBY P, EBERT B L. CHIP (clonal hematopoiesis of indeterminate potential): potent and newly recognized contributor to cardiovascular risk[J]. Circulation, 2018, 138(7): 666-668. DOI: 10.1161/CIRCULATIONAHA.118.034392.
JAISWAL S, FONTANILLAS P, FLANNICK J, et al . Age-related clonal hematopoiesis associated with adverse outcomes[J ] . N Engl J Med, 2014, 371(26): 2488-2498. DOI: 10.1056/NEJMoa1408617.
STEENSMA D P, BEJAR R, JAISWAL S, et al . Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes[J ] . Blood, 2015, 126(1): 9-16. DOI: 10.1182/blood-2015-03-631747.
GENOVESE G, KAHLER A K, HANDSAKER R E, et al . Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence[J ] . N Engl J Med, 2014, 371(26): 2477-2487. DOI: 10.1056/NEJMoa1409405.
BOLTON K L, KOH Y, FOOTE M B, et al . Clonal hematopoiesis is associated with risk of severe Covid-19[J ] . Nat Commun, 2021, 12(1): 5975. DOI: 10.1038/s41467-021-26138-6.
PASUPULETI S K, RAMDAS B, BURNS S S, et al . Obesity-induced inflammation exacerbates clonal hematopoiesis[J ] . J Clin Invest, 2023, 133(11): e163968. DOI: 10.1172/JCI163968.
DAWOUD A A Z, GILBERT R D, TAPPER W J, et al . Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease[J ] . Leukemia, 2022, 36(2): 507-515. DOI: 10.1038/s41375-021-01382-3.
HAGE F G, VENKATARAMAN R, ZOGHBI G J, et al . The scope of coronary heart disease in patients with chronic kidney disease[J ] . J Am Coll Cardiol, 2009, 53(23): 2129-2140. DOI: 10.1016/j.jacc.2009.02.047.
JAISWAL S, NATARAJAN P, SILVER A J, et al . Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease[J ] . N Engl J Med, 2017, 377(2): 111-121. DOI: 10 .1056/NEJMoa1701719.
PARFREY P S, FOLEY R N. The clinical epidemiology of cardiac disease in chronic renal failure[J]. J Am Soc Nephrol, 1999, 10(7): 1606-1615. DOI: 10.1681/ASN.V1071606.
LI C, HU D Y, SHI X B, et al . A multicentre prospective evaluation of the impact of renal insufficiency on in-hospital and long-term mortality of patients with acute ST-elevation myocardial infarction[J ] . Chin Med J, 2015, 128(1): 1-6. DOI: 10.4103/0366-6999.147330.
ROSS R. Atherosclerosis: an inflammatory disease[J]. N Engl J Med, 1999, 340(2): 115-126. DOI: 10.1056/NEJM199901143400207.
LEVEYA S, STEVENS L A, SCHMID C H, et al . A new equation to estimate glomerular filtration rate[J ] . Ann Intern Med, 2009, 150(9): 604-612. DOI: 10.7326/0003-4819-150-9-200905050-00006.
WANG J, LI Y, GUO Y K, et al . The adverse impactof coronary artery disease on left ventricle systolic and diastolic function in patients with type 2 diabetes mellitus: a 3.0T CMR study[J ] . Cardiovasc Diabetol, 2022, 21(1): 30. DOI: 10.1186/s12933-022-01467-y.
WANG J, YANG Z G, GUO Y K, et al . Incremental effect of coronary obstruction on myocardial microvascular dysfunction in type 2 diabetes mellitus patients evaluated by first-pass perfusion CMR study[J ] . Cardiovasc Diabetol, 2023, 22(1): 154. DOI: 10.1186/s12933-023-01873-w.
ANH D T, MINH H V, BINH H A, et al . Age related differences in acute coronary syndrome: an observation at a central hospital in Vietnam[J ] . J Transl Int Med, 2021, 9(1): 32-37. DOI: 10.2478/jtim-2021-0012.
JIANG Z X, LI Y, YAN C H, et al . Clonal hematopoiesis of indeterminate potential in patients with acute coronary syndrome undergoing percutaneous coronary intervention in the absence of traditional risk factors[J ] . Clin Res Cardiol, 2023, 112(4): 506-517. DOI: 10.1007/s00392-022-02039-6.
AKHIYAT N, LASHO T, GANJI M, et al . Clonal hematopoiesis of indeterminate potential is associated with coronary microvascular dysfunction in early nonobstructive coronary artery disease[J ] . Arterioscler Thromb Vasc Biol, 2023, 43(5): 774-783. DOI: 10.1161/ATVBAHA.122.318928.
VLASSCHAERT C, MCNAUGHTON A J M, CHONG M, et al . Associa tion of clonal hematopoiesis of indeterminate potential with worse kidney function and anemia in two cohorts of patients with advanced chronic kidney disease[J ] . J Am Soc Nephrol, 2022, 33(5): 985-995. DOI: 10.1681/ASN.2021060774.
WANG S F, HU S N, LUO X, et al . Prevalence and prognostic significance of DNMT3A- and TET2- clonal haematopoiesis-driver mutations in patients presenting with ST-segment elevation myocardial infarction[J ] . EBioMedicine, 2022, 78: 103964. DOI: 10.1016/j.ebiom.2022.103964.
GENSINI G G. A more meaningful scoring system for determining the severity of coronary heart disease[J]. Am J Cardiol, 1983, 51(3): 606. DOI: 10.1016/s0002-9149(83)80105-2.
JAISWAL S, LIBBY P. Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease[J]. Nat Rev Cardiol, 2020, 17(3): 137-144. DOI: 10.1038/s41569-019-0247-5.
AVAGYAN S, ZON L I. Clonal hematopoiesis and inflammation—the perpetual cycle[J]. Trends Cell Biol, 2023, 33(8): 695-707. DOI: 10.1016/j.tcb.2022.12.001.
JAISWAL S, FONTANILLAS P, FLANNICK J, et al . Age-related clonal hematopoiesis associate d with adverse outcomes[J ] . N Engl J Med, 2014, 371(26): 2488-2498. DOI: 10.1056/NEJMoa1408617.
KLEIBLOVA P, SHALTIEL I A, BENADA J, et al . Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint[J ] . J Cell Biol, 2013, 201(4): 511-521. DOI: 10.1083/jcb.201210031.
YURA Y, MIURA-YURA E, KATANASAKA Y, et al . The cancer therapy-related clonal hematopoiesis driver gene Ppm 1 d promotes inflammation and non-ischemic heart failure in mice[J ] . Circ Res, 2021, 129(6): 684-698. DOI: 10.1161/CIRCRESAHA.121.319314..
WANG S Y, PASCA S, POST W S, et al . Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis[J ] . AIDS, 2022, 36(11): 1521-1531. DOI: 10.1097/QAD.0000000000003280.
BICK A G, POPADIN K, THORBALL C W, et al . Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV[J ] . Sci Rep, 2022, 12(1): 577. DOI: 10.1038/s41598-021-04308-2.
MARNELL C S, BICK A, NATARAJAN P. Clonal hematopoiesis of indeterminate potential (CHIP): linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease[J]. J Mol Cell Cardiol, 2021, 161: 98-105. DOI: 10.1016/j.yjmcc.2021.07.004.
POLIZIO A H, PARK E, WALSH K. Clonal hematopoiesis: connecting aging and inflammation in atherosclerosis[J]. Curr Atheroscler Rep, 2023, 25(3): 105-111. DOI: 10.1007/s11883-023-01083-5.
FUSTER J J, MACLAUCHLAN S, ZURIAGA M A, et al . Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice[J ] . Science, 2017, 355(6327): 842-847. DOI: 10.1126/science.aag1381.
ZHANG Q, ZHAO K, SHEN Q C, et al . Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6[J ] . Nature, 2015, 525(7569): 389-393. DOI: 10.1038/nature15252.
YU B, ROBERTS M B, RAFFIELD L M, et al . Supplemental association of clonal hematopoiesis with incident heart failure[J ] . J Am Coll Cardiol, 2021, 78(1): 42-52. DOI: 10.1016/j.jacc.2021.04.085.
LIBBY P, SIDLOW R, LIN A E, et al . Clonal hematopoiesis: crossroads of aging, cardiovascular disease, and cancer: J ACC review topic of the week[J ] . J Am Coll Cardiol, 2019, 74(4): 567-577. DOI: 10.1016/j.jacc.2019.06.007.
0
Views
0
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010802024621
